Characteristics and outcomes in common PTCL subtypes5,6
| PTCL subtype . | N . | Median age (years) . | Percent IPI . | 5-year OS* . | 5-year FFS* . | 5-year OS by IPI . | |||
|---|---|---|---|---|---|---|---|---|---|
| 0-1 . | 2-3 . | 4-5 . | 0-1 . | 4-5 . | |||||
| PTCL-NOS | |||||||||
| IPTCL | 229 | 60 | 28 | 57 | 15 | 32% | 20% | 50% | 11% |
| BCCA | 117 | 64 | 30 | 47 | 22 | 35% | 29% | 64% | 22% |
| AITL | |||||||||
| IPTCL | 213 | 65 | 14 | 59 | 28 | 32% | 18% | 56% | 25% |
| BCCA | 10 | 66 | 0 | 30 | 70 | 36% | 13% | NR | NR |
| ALCL ALK− | |||||||||
| IPTCL | 72 | 58 | 41 | 44 | 15 | 49% | 36% | 74% | 13% |
| BCCA | 18 | 55 | 44 | 22 | 33 | 34% | 28%† | 66%† | 25%† |
| ALCL ALK+ | |||||||||
| IPTCL | 76 | 34 | 49 | 37 | 14 | 70% | 60% | 90% | 33% |
| BCCA | 12 | 32 | 67 | 25 | 8 | 58% | 28%† | 66%† | 25%† |
| PTCL subtype . | N . | Median age (years) . | Percent IPI . | 5-year OS* . | 5-year FFS* . | 5-year OS by IPI . | |||
|---|---|---|---|---|---|---|---|---|---|
| 0-1 . | 2-3 . | 4-5 . | 0-1 . | 4-5 . | |||||
| PTCL-NOS | |||||||||
| IPTCL | 229 | 60 | 28 | 57 | 15 | 32% | 20% | 50% | 11% |
| BCCA | 117 | 64 | 30 | 47 | 22 | 35% | 29% | 64% | 22% |
| AITL | |||||||||
| IPTCL | 213 | 65 | 14 | 59 | 28 | 32% | 18% | 56% | 25% |
| BCCA | 10 | 66 | 0 | 30 | 70 | 36% | 13% | NR | NR |
| ALCL ALK− | |||||||||
| IPTCL | 72 | 58 | 41 | 44 | 15 | 49% | 36% | 74% | 13% |
| BCCA | 18 | 55 | 44 | 22 | 33 | 34% | 28%† | 66%† | 25%† |
| ALCL ALK+ | |||||||||
| IPTCL | 76 | 34 | 49 | 37 | 14 | 70% | 60% | 90% | 33% |
| BCCA | 12 | 32 | 67 | 25 | 8 | 58% | 28%† | 66%† | 25%† |
ALCL ALK−, anaplastic large cell lymphoma anaplastic lymphoma kinase negative (−); ALCL ALK+, anaplastic large cell lymphoma anaplastic lymphoma kinase positive (+); N, number; NR, not reported.
Data from International T-Cell Lymphoma Project in which >85% patients received an anthracycline-based regimen without upfront transplant.
BCCA ALCL reported as both ALK + and –.